Trastuzumab beyond progression in HER2-positive metastatic breast cancer

被引：1
作者：
Al-Naqqash, Manwar [1 ,2 ]
Jasim Al-Serarati, Waleed [3 ]
Farooq Kareem, Tara [4 ]
机构：
[1] Univ Baghdad, Dept Surg, Coll Med, Baghdad 10001, Iraq
[2] Minist Hlth Environm, Dept Radiat Oncol, Oncol Teaching Hosp, Baghdad Med City Complex, Baghdad, Iraq
[3] Minist Hlth & Environm, Dept Oncol, Baghdad Med City Complex, Baghdad, Iraq
[4] Minist Hlth & Environm, Oncol Teaching Hosp, Dept Diagnost Radiol, Baghdad Med City Complex, Baghdad, Iraq
来源：
BREAST JOURNAL | 2021年 / 27卷 / 03期
关键词：
breast cancer; HER2; neu; time to progression; trastuzumab;
D O I：
10.1111/tbj.14157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：297 / 299
页数：3
相关论文
共 50 条
  • [21] TRASTUZUMAB BEYOND PROGRESSION IN PATIENTS WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER
    Eralp, Yesim
    JOURNAL OF BREAST HEALTH, 2009, 5 (01): : 3 - 8
  • [22] Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
    Taveira, Mateus de Oliveira
    Nabavi, Sheida
    Wang, Yuker
    Tonellato, Peter
    Esteva, Francisco J.
    Cantley, Lewis C.
    Wulf, Gerburg M.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (07) : 1255 - 1262
  • [23] A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer
    Tolaney, S. M.
    Najita, J.
    Sperinde, J.
    Huang, W.
    Chen, W. Y.
    Savoie, J.
    Fornier, M.
    Winer, E. P.
    Bunnell, C.
    Krop, I. E.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1841 - 1847
  • [24] Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
    Mateus de Oliveira Taveira
    Sheida Nabavi
    Yuker Wang
    Peter Tonellato
    Francisco J. Esteva
    Lewis C. Cantley
    Gerburg M. Wulf
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 1255 - 1262
  • [25] HER-2-positive metastatic breast cancer: trastuzumab and beyond
    Metro, Giulio
    Mottolese, Marcella
    Fabi, Alessandra
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (15) : 2583 - 2601
  • [26] Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission
    Haq, R.
    Gulasingam, P.
    CURRENT ONCOLOGY, 2016, 23 (02) : 91 - 95
  • [27] Treatment of HER2-Positive Metastatic Breast Cancer Following Initial Progression
    Mayer, Ingrid A.
    CLINICAL BREAST CANCER, 2009, 9 : S50 - S57
  • [28] Trastuzumab In HER2-Positive Metastatic Gastric Cancer
    Croxtall, Jamie D.
    McKeage, Kate
    DRUGS, 2010, 70 (17) : 2259 - 2267
  • [29] HER2-positive metastatic breast cancer: A changing scenario
    Mustacchi, G.
    Biganzoli, L.
    Pronzato, P.
    Montemurro, F.
    Dambrosio, M.
    Minelli, M.
    Molteni, L.
    Scaltriti, L.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (01) : 78 - 87
  • [30] Optimizing the Management of Metastatic HER2-Positive Breast Cancer
    Goel S.
    Tolaney S.
    Current Breast Cancer Reports, 2015, 7 (4) : 190 - 202
12345